Gilead Sciences, Inc. (BMV:GILD)

Market Cap	2.78T
Revenue (ttm)	544.30B
Net Income (ttm)	119.01B
Shares Out	n/a
EPS (ttm)	94.50
PE Ratio	23.35
Forward PE	14.19
Dividend	61.48 (2.74%)
Ex-Dividend Date	Jun 13, 2025

Volume	109
Average Volume	657
Open	2,260.00
Previous Close	2,217.27
Day's Range	2,241.10 - 2,260.00
52-Week Range	1,390.00 - 2,347.00
Beta	0.35
RSI	67.00
Earnings Date	Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD